GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Shore Capital's recent research note on GSK PLC (LSE:GSK, NYSE:GSK) paints an optimistic picture for the pharmaceutical giant, underlining reasons for maintaining a 'Buy' recommendation with a raised fair value to 2,000p, up from 1,850p. The note points out that GSK's current market valuation, trading at a price-to-earnings ratio (PER) of approximately nine times for the financial year 2025 (FY25F), is significantly lower than its peers, averaging around 15 times.

Is GSK worth £20 a share? This broker seems to thinks so

Deutsche Bank

GSK has received a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in a sector with a mixed outlook in 2024. “Top-down, our sector view remains neutral and perhaps even more incrementally cautious for 2023 relative to FY23; however we do have a very clear rank order of preferences, with Novo, GSK and Novartis our buy recommendations.

GSK still a top pick in pharma sector for Deutsche Bank

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

Agenus

Bristol-Myers

Compugen

iTeos Therapeutics, Inc.

Merck

Novartis

Pfizer

Arcus Biosciences

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript)

British pharmaceutical giant GSK PLC on Tuesday announced a $1.4 billion deal to acquire Aiolos Bio Inc., boosting its respiratory portfolio.

GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition

GSK PLC (LSE:GSK, NYSE:GSK) should deliver better than expected fourth-quarter results on January 31, according to Barclays, amid heightened expectations driven by the robust performance of its RSV vaccine, Arexvy. Analysts at the bank, who also wondered if 2024 could be "the year Zantac goes away?

GSK strong finish expected, says Barclays

SAN FRANCISCO & LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. The acquisition provides GSK with access.

GSK Enters Agreement to Acquire Aiolos Bio

GSK on Tuesday said it had struck a deal to acquire asthma drug developer Aiolos Bio for up to $1.4 billion, as the British pharmaceutical giant pushes forward with plans to bolster its development pipeline by snapping up autoimmune and respiratory focused biotech companies.

GSK to buy asthma drug developer for up to $1.4 billion in pipeline push

GSK PLC (LSE:GSK, NYSE:GSK) has moved to bolster its respiratory franching with the acquisition of Aiolos Bio for up to $1.4bn. It is paying an upfront $1 billion and $400 million based on certain regulator milestones.

GSK to pay up to $1.4bn for respiratory acquisition

GSK said it has bought Aiolos Bio for an upfront consideration of $1 billion, with the potential for an additional $400 million.

GSK Buys Asthma-Focused Aiolos

British drugmaker GSK on Tuesday said it would acquire clinical-stage biopharmaceutical firm Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.

GSK to acquire Aiolos Bio in $1.4 bln deal

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Glaxo (GSK) is Poised to Beat Earnings Estimates Again

BlackBerry

First Solar

Wall Street's views on stocks and sectors can change tremendously in a short time. For example, in early 2022, the Street was sure that Luckin Coffee (OTC: LKNCY ) was dead and buried.

Sleeper Hits: 3 Unexpected Stocks Poised for a Breakout in 2024

AstraZeneca

GSK PLC (LSE:GSK, NYSE:GSK) shares got a shot in the arm this morning after Jefferies took a more positive view of the pharmaceuticals giant. The US investment bank upgraded its rating to ‘buy' from ‘hold' and increased its price target to 1,900p from 1,550p.

GSK gets shot in arm from upgrade, AstraZeneca mixed reviews after China deal

GSK (GSK) concluded the recent trading session at $37.51, signifying a +1.21% move from its prior day's close.

GSK (GSK) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, GSK (GSK) closed at $37.10, indicating a +0.24% shift from the previous trading day.

GSK (GSK) Rises Higher Than Market: Key Facts

AbbVie

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product launches, and strategic investments make it an attractive investment option.

AbbVie Vs. GSK: Dual Dominance In Pharma

Drugmaker GSK Plc said on Friday that it will cut U.S. list prices on asthma drug Advair, herpes drug Valtrex, and anti-epileptic medication Lamictal on Jan. 1, 2024.

GSK to cut US prices for Advair, Valtrex and Lamictal

Micron Technology

Wendy's

Growth at a reasonable price (GARP) stocks represent a middle ground between growth stocks with high valuations and very conservative value stocks. While growth stocks with high valuations could easily plunge or even go to $0 due to bankruptcy, GARP stocks are unlikely to do either.

3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth

GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.

GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate

GSK PLC GSK, +0.11% said Wednesday that it has agreed to pay $185 million up front and up to $1.525 billion in success-based milestone payments to license an antibody-drug conjugate from Chinese biopharma company Hansoh Pharma. The deal gives GSK exclusive rights to further develop and commercialize the ADC, HS-20093, which in early studies has shown promise for the treatment of lung cancer.

GSK agrees to pay up to $1.7 billion for antibody-drug conjugate

Eli Lilly

Novo Nordisk

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

5 Big Drug Stocks That May Continue to Outperform in 2024

GSK said on Monday that a combination of its cancer drugs Zejula and Jemperli, when as used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer.

GSK's cancer drug combination meets primary goal in late-stage trial

GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immuno-therapy Jemperli had shown promise when used in harness with an existing cancer drug Zejula when treating advanced or recurrent endometrial forms of the killer disease. Its RUBY Part 2 phase III trial revealed the combination significantly improved the progression-free survival of patients.

News for GlaxoSmithKline Stock (GSK)